60 Degrees, Tufts Medical Center announces patent license agreement

60 Degrees Pharmaceuticals (SXTP) and Tufts Medical Center announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. Tafenoquine is not currently approved by the U.S. Food and Drug Administration for the treatment and prevention of babesiosis. The agreement follows initiation of collaboration between researchers from both organizations to study the activity of tafenoquine against babesiosis, a serious tick-borne disease caused by microscopic parasites that infect red blood cells. The study formed the basis of U.S. Provisional Patent Application No. 63/461,060, and related U.S. utility and PCT applications, granting the parties shared intellectual property rights to tafenoquine’s potential future use for babesiosis. Joint Patent Ownership: 60 Degrees and Tufts MC will co-own patent applications related to tafenoquine for babesiosis, with the Company leading prosecution and maintenance activities worldwide. Commercialization Rights: 60 Degrees holds exclusive global rights to commercialize tafenoquine for babesiosis, including sublicensing to third parties for product development and sales. Research Collaboration: Tufts MC retains a royalty-free, global license for research purposes, further advancing innovation in this area. Royalties and Revenue Sharing: Tufts MC will receive royalties on net sales of tafenoquine-based products labeled for babesiosis treatment or prevention. Commitment to Development: 60 Degrees has committed to using commercially reasonable efforts to bring tafenoquine products to market and to expanding access to innovative therapies for babesiosis.